Kaveh Zakeri1, Deepa Narayanan2, Bhadrasain Vikram3, Greg Evans2, C Norman Coleman3, Pataje G S Prasanna4. 1. Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California. 2. Small Business Innovation Research Development Center, National Cancer Institute, Bethesda, Maryland. 3. Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland. 4. Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland. Electronic address: Pat.Prasanna@nih.gov.
Abstract
PURPOSE: The use of radioprotectors and radiomitigators could improve the therapeutic index of radiation therapy. With the intention of accelerating translation of radiation-effect modulators (radioprotectors and mitigators), the Radiation Research Program and SBIR (Small Business Innovation Research) Development Center within the National Cancer Institute issued 4 Requests for Proposals (RFPs) from 2010 to 2013. Twelve SBIR contract awards in total were made in response to the 4 RFPs from September 2011 through September 2014. Here, we provide an update on the status of SBIR contract projects for the development of radiation-effect modulators. METHODS AND MATERIALS: To assess the status of research and development efforts under the 4 RFPs on radiation-effect modulators, we searched PubMed for research articles, google.com for published abstracts, clinicaltrials.gov for ongoing or completed clinical trials, and company websites for press releases and other news. All information obtained and reported here is publicly available and thus protects the intellectual property of the investigators and companies. RESULTS: Of the 12 SBIR projects funded, 5 (42%) transitioned successfully from phase 1 to phase 2 SBIR funding, and among the Fast-Track contracts, this rate was 100% (3 of 3). The Internet search identified 3 abstracts and 6 publications related to the aims of the SBIR contracts. One-third of the companies (4 of 12) have successfully launched a total of 8 clinical trials to demonstrate the safety and efficacy of their investigational agents. Two drugs are in clinical trials for their indication as a radioprotector, and 2 drugs are under evaluation for their anticancer properties (an immunomodulator and a small molecule inhibitor). CONCLUSIONS: The National Cancer Institute's SBIR has provided pivotal funding to small businesses for the development of radioprotectors and radiomitigators, which resulted in multiple early-phase clinical trials. Longer follow-up is needed to determine the full impact of these novel therapeutics that enter clinical practice. Published by Elsevier Inc.
PURPOSE: The use of radioprotectors and radiomitigators could improve the therapeutic index of radiation therapy. With the intention of accelerating translation of radiation-effect modulators (radioprotectors and mitigators), the Radiation Research Program and SBIR (Small Business Innovation Research) Development Center within the National Cancer Institute issued 4 Requests for Proposals (RFPs) from 2010 to 2013. Twelve SBIR contract awards in total were made in response to the 4 RFPs from September 2011 through September 2014. Here, we provide an update on the status of SBIR contract projects for the development of radiation-effect modulators. METHODS AND MATERIALS: To assess the status of research and development efforts under the 4 RFPs on radiation-effect modulators, we searched PubMed for research articles, google.com for published abstracts, clinicaltrials.gov for ongoing or completed clinical trials, and company websites for press releases and other news. All information obtained and reported here is publicly available and thus protects the intellectual property of the investigators and companies. RESULTS: Of the 12 SBIR projects funded, 5 (42%) transitioned successfully from phase 1 to phase 2 SBIR funding, and among the Fast-Track contracts, this rate was 100% (3 of 3). The Internet search identified 3 abstracts and 6 publications related to the aims of the SBIR contracts. One-third of the companies (4 of 12) have successfully launched a total of 8 clinical trials to demonstrate the safety and efficacy of their investigational agents. Two drugs are in clinical trials for their indication as a radioprotector, and 2 drugs are under evaluation for their anticancer properties (an immunomodulator and a small molecule inhibitor). CONCLUSIONS: The National Cancer Institute's SBIR has provided pivotal funding to small businesses for the development of radioprotectors and radiomitigators, which resulted in multiple early-phase clinical trials. Longer follow-up is needed to determine the full impact of these novel therapeutics that enter clinical practice. Published by Elsevier Inc.
Authors: A Dimitrios Colevas; J Martin Brown; Stephen Hahn; James Mitchell; Kevin Camphausen; C Norman Coleman Journal: J Natl Cancer Inst Date: 2003-05-07 Impact factor: 13.506
Authors: Lyudmila G Burdelya; Anatoli S Gleiberman; Ilia Toshkov; Semra Aygun-Sunar; Meghana Bapardekar; Patricia Manderscheid-Kern; David Bellnier; Vadim I Krivokrysenko; Elena Feinstein; Andrei V Gudkov Journal: Int J Radiat Oncol Biol Phys Date: 2011-10-14 Impact factor: 7.038
Authors: Carolyn D Britten; Elizabeth Garrett-Mayer; Steven H Chin; Keisuke Shirai; Besim Ogretmen; Tricia A Bentz; Alan Brisendine; Kate Anderton; Susan L Cusack; Lynn W Maines; Yan Zhuang; Charles D Smith; Melanie B Thomas Journal: Clin Cancer Res Date: 2017-04-18 Impact factor: 12.531
Authors: Deborah E Citrin; Pataje G S Prasanna; Amanda J Walker; Michael L Freeman; Iris Eke; Mary Helen Barcellos-Hoff; Molykutty J Arankalayil; Eric P Cohen; Ruth C Wilkins; Mansoor M Ahmed; Mitchell S Anscher; Benjamin Movsas; Jeffrey C Buchsbaum; Marc S Mendonca; Thomas A Wynn; C Norman Coleman Journal: Radiat Res Date: 2017-05-10 Impact factor: 2.841
Authors: Ilia A Toshkov; Anatoli S Gleiberman; Vadim L Mett; Alan D Hutson; Anurag K Singh; Andrei V Gudkov; Lyudmila G Burdelya Journal: Radiat Res Date: 2017-03-21 Impact factor: 2.841
Authors: Barbara Olszewska-Pazdrak; Scott D McVicar; Kempaiah Rayavara; Stephanie M Moya; Carla Kantara; Chris Gammarano; Paulina Olszewska; Gerald M Fuller; Laurie E Sower; Darrell H Carney Journal: Radiat Res Date: 2016-07-07 Impact factor: 2.841
Authors: Pataje G S Prasanna; Deepa Narayanan; Kory Hallett; Eric J Bernhard; Mansoor M Ahmed; Gregory Evans; Bhadrasain Vikram; Michael Weingarten; C Norman Coleman Journal: Radiat Res Date: 2015-08-18 Impact factor: 2.841
Authors: Shayne Cox Gad; Dexter W Sullivan; Ivan Spasojevic; Cesar V Mujer; Charles B Spainhour; James D Crapo Journal: Int J Toxicol Date: 2016-04-20 Impact factor: 2.032
Authors: Isabel L Jackson; Andrew Zodda; Ganga Gurung; Radmila Pavlovic; Michael D Kaytor; Michael A Kuskowski; Zeljko Vujaskovic Journal: Br J Pharmacol Date: 2017-11-03 Impact factor: 8.739
Authors: Jeffrey C Buchsbaum; Michael G Espey; Ceferino Obcemea; Jacek Capala; Mansoor Ahmed; Pataje G Prasanna; Bhadrasain Vikram; Julie A Hong; Beverly Teicher; Molykutty J Aryankalayil; Michelle A Bylicky; C Norman Coleman Journal: J Clin Oncol Date: 2022-03-04 Impact factor: 50.717
Authors: Clarissa G C Maia; Bárbara C R de Araujo; Maria B de Freitas-Marques; Israel F da Costa; Maria Irene Yoshida; Wagner da Nova Mussel; Rita de Cássia O Sebastião; Júlio S Rebouças Journal: Oxid Med Cell Longev Date: 2021-12-06 Impact factor: 6.543
Authors: Pataje G Prasanna; Deborah E Citrin; Jeffrey Hildesheim; Mansoor M Ahmed; Sundar Venkatachalam; Gabriela Riscuta; Dan Xi; Guangrong Zheng; Jan van Deursen; Jorg Goronzy; Stephen J Kron; Mitchell S Anscher; Norman E Sharpless; Judith Campisi; Stephen L Brown; Laura J Niedernhofer; Ana O'Loghlen; Alexandros G Georgakilas; Francois Paris; David Gius; David A Gewirtz; Clemens A Schmitt; Mohamed E Abazeed; James L Kirkland; Ann Richmond; Paul B Romesser; Scott W Lowe; Jesus Gil; Marc S Mendonca; Sandeep Burma; Daohong Zhou; C Norman Coleman Journal: J Natl Cancer Inst Date: 2021-10-01 Impact factor: 11.816